Sergey Terushkin, MD, FACS, is a board-certified bariatric surgeon with 15+ years of experience, offering medical weight loss, GLP-1 therapies, and bariatric procedures at Florida Surgery And Weight Loss Center
This container becomes the one place your semaglutide always lives when not in your hand
Its a more comprehensive treatment for fat loss while improving body composition
Begin with a sensible diet, some exercise, and medical oversight
Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs
Rapid Onset of Action: Medications absorbed sublingually can enter the bloodstream more quickly than those absorbed through the digestive system, potentially leading to a faster onset of action
